Avacta Group PLC Avacta's CEO to Present at Biotech Investor Day
July 29 2019 - 2:01AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
29 July 2019
29 July 2019
Avacta Group plc
("Avacta", the "Company" or the "Group")
Avacta's Chief Executive Officer to Present at the Solebury
Trout European Biotech Investor Day in New York
Avacta Group plc (AIM: AVCT), a biotechnology company developing
novel cancer immunotherapies based on its proprietary Affimer(R)
platform, is pleased to announce that its Chief Executive Officer,
Dr Alastair Smith, will present at the European Biotech Investor
Day in New York City in the New York Times building on Thursday,
August 1(st) organised by Solebury Trout and sponsored by Goodwin
LLC, Deutsche Bank, H.C. Wainwright and Nasdaq.
Alastair's presentation will discuss the Company's drug
development pipeline based on the combination of Affimer
immunotherapies with tumour targeted chemotherapy aimed at
addressing the lack of a durable response to current
immunotherapies experienced by most cancer patients.
The presentation will be made available on the Company's
website: https://www.avacta.com/investors/documents.
- Ends -
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial
Officer
finnCap Ltd (Nominated Adviser Tel: +44 (0) 207 220 0500
and Joint Broker) www.finncap.com
Geoff Nash / Giles Rolls - Corporate
Finance
Tim Redfern - ECM Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
WG Partners (Joint Broker) www.wgpartners.co.uk
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang
Turner Pope Investments Tel: +44 (0) 203 621 4120
James Pope / Ben Turner www.turnerpope.com
Yellow Jersey PR (Financial Media
and IR) Tel: +44 (0)7764 947 137
Sarah Hollins Tel: +44 (0)7544 275 882
Harriet Jackson avacta@yellowjerseypr.com
Zyme Communications (Trade and Tel: +44 (0)7787 502 947
Regional Media) katie.odgaard@zymecommunications.com
Katie Odgaard
About Avacta Group plc - https://www.avacta.com
Avacta is developing novel cancer immunotherapies combining its
two proprietary platforms - Affimer(R) biotherapeutics and tumour
targeted chemotherapy. With this approach, the Company aims to
address the lack of a durable response to current immunotherapies
experienced by most patients.
The Affimer platform is an alternative to antibodies derived
from a small human protein. Despite their shortcomings, antibodies
currently dominate markets worth in excess of $100bn. Affimer
technology has been designed to address many of these negative
performance issues, principally: the time taken, and the reliance
on an animal's immune response, to generate new antibodies; poor
specificity in many cases; large size and cost.
Avacta's proprietary targeted chemotherapy platform, releases
active drug only in the tumour, thereby limiting systemic exposure
and improving the overall safety and therapeutic potential of these
powerful anti-cancer treatments.
By combining these two platforms the Company is building a
wholly owned pipeline of novel cancer therapies with the aim of
creating effective treatments for all cancer patients including
those who do not respond to existing immunotherapies. Avacta
expects to take its first programme into the clinic in the first
half of 2020.
Avacta has established drug development partnerships with pharma
and biotech, including with Moderna Therapeutics Inc., and a deal
with LG Chem worth up to $310m, and actively seeks to license its
proprietary platforms in a range of therapeutic areas. The Company
benefits from near-term revenues generated from Affimer reagents
for diagnostics, bioprocessing and research, through a separate
business unit.
To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
About the European Biotech Investor Day
The European Biotech Investor Day in NYC, features
privately-held and EU-listed biotechnology companies representing
the "Next Wave of Opportunities" emerging from Europe.
Participating companies offer compelling or novel approaches to
addressing a range of indications. To inquire about Solebury Trout
or to attend the event, please contact Thomas Hoffman at
thoffmann@troutgroup.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALLFSSDTIRFIA
(END) Dow Jones Newswires
July 29, 2019 02:01 ET (06:01 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024